High throughput physiological screening of iPSC-derived cardiomyocytes for drug development.
about
Inherited heart disease - what can we expect from the second decade of human iPS cell research?Interleukin-18 deteriorates Fabry cardiomyopathy and contributes to the development of left ventricular hypertrophy in Fabry patients with GLA IVS4+919 G>A mutationMulti-Imaging Method to Assay the Contractile Mechanical Output of Micropatterned Human iPSC-Derived Cardiac Myocytes.Electrophysiological Analysis of human Pluripotent Stem Cell-derived Cardiomyocytes (hPSC-CMs) Using Multi-electrode Arrays (MEAs)Phenotypic assays for analyses of pluripotent stem cell-derived cardiomyocytes.Stem Cells in Cardiovascular Medicine: the Road to Regenerative Therapies.Immunogenicity and antimicrobial effectiveness of Pseudomonas aeruginosa specific bacteriophage in a human lung in vitro model.An Automated Platform for Assessment of Congenital and Drug-Induced Arrhythmia with hiPSC-Derived CardiomyocytesTailoring Mathematical Models to Stem-Cell Derived Cardiomyocyte Lines Can Improve Predictions of Drug-Induced Changes to Their Electrophysiology.Pluripotent Stem Cell-Derived Human Tissue: Platforms to Evaluate Drug Metabolism and Safety.Pluripotent Stem Cell-Derived Cardiomyocytes as a Platform for Cell Therapy Applications: Progress and Hurdles for Clinical Translation.Is Human-induced Pluripotent Stem Cell the Best Optimal?
P2860
Q28079217-526DE380-5E3C-4274-A7E5-842FC66F24C7Q37699393-BDC7C7C2-BEC6-450B-911C-B1759744B92EQ38731678-2BF2B049-E452-46C6-B333-5C55C77C95B2Q38750884-4EDBF7F5-0182-4B37-8F0A-D67C67333A88Q39044287-E8494268-43F0-4B4C-BECF-1BD90EEEB790Q39190689-F546DE6E-A90A-4B43-BBF8-116BF9F82277Q40044171-3476D080-16DF-4176-B6C8-A4FF0F3570F3Q42700209-B8D1B3B9-43E0-4970-A8AA-CCDFCF15A6FFQ47194710-7BCB56C8-BBAE-49EE-85F0-E93FA63ADFA7Q47225797-8A136C61-30AE-4A33-8FBF-57021D1263E1Q52560413-3937C13B-BF6B-4E91-823C-465EB23DB6B3Q52631688-6DD5BDE8-9821-4385-A1D4-7624626A9FBC
P2860
High throughput physiological screening of iPSC-derived cardiomyocytes for drug development.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
High throughput physiological ...... myocytes for drug development.
@en
type
label
High throughput physiological ...... myocytes for drug development.
@en
prefLabel
High throughput physiological ...... myocytes for drug development.
@en
P2093
P2860
P1476
High throughput physiological ...... omyocytes for drug development
@en
P2093
Derek Lemons
Fabio Cerignoli
Mark Mercola
Ricardo Serrano
Rolf Bodmer
P2860
P304
P356
10.1016/J.BBAMCR.2016.03.003
P407
P433
P577
2016-03-04T00:00:00Z